Close menu




Comments

Photo credits: pixabay.com

Commented by Armin Schulz on November 21st, 2022 | 14:22 CET

BYD, dynaCERT, Plug Power - Sustainable shares for the portfolio

  • Hydrogen
  • greenhydrogen
  • Electromobility

The end of fossil fuels is inevitable. The only question is how quickly we can make the transition. And the answer to that question will determine the extent of the impact of climate change. Last year alone, more than USD 6 billion was pledged to phase out fossil fuels. And this trend will only intensify. The Paris Agreement, signed by nearly 200 countries in 2016, set a goal of limiting global warming to below 2°C. Vehicles with internal combustion engines are major emitters of emissions. If we succeed in reducing CO2 emissions here, we will be closer to achieving the targets. Today we take a look at three companies that are helping to make mobility more environmentally friendly.

Read

Commented by Nico Popp on November 21st, 2022 | 12:11 CET

Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer

  • Biotechnology

Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.

Read

Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET

Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off

  • Biotechnology
  • Investments

After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.

Read

Commented by Juliane Zielonka on November 18th, 2022 | 11:25 CET

Pfizer, Cardiol Therapeutics, Morphosys - Heart disease and cancer are on the rise!

  • Biotechnology
  • Cancer
  • heartdisease

No sooner is the Coronavirus in retreat than the damage caused by the pandemic measures comes to light. Young men, in particular, are affected by heart inflammation after two vaccinations with the Pfizer or Moderna vaccine. Reason enough for both companies to react to the research results of a small Canadian study with a new study that brought exactly that to light. On the other hand, the increase in myocarditis and pericarditis represents a great opportunity for Cardiol Therapeutics to successfully develop its active ingredient against pericarditis. So far, there is only one treatment available in the US that is purely inpatient, and it is in the five-digit USD range. With Cardiol's active ingredient, it may be possible to contain pericarditis more economically and effectively. Another consequence of the pandemic is an increase in cancer cases. Due to late diagnosis and a lack of access to health care, cancer is becoming a global health problem. Morphosys, still reeling this week from disappointing Alzheimer's trial results, however, has promising drugs in the pipeline.

Read

Commented by Fabian Lorenz on November 18th, 2022 | 10:15 CET

Shares of Nordex, BYD, and Almonty Industries: Winners of the energy transition

  • Mining
  • Tungsten
  • Electromobility

The energy turnaround is becoming unbearable. But it will take time for the world to switch to renewable energies in private and public life. Today, we take a look at three winning stocks. Among them is BYD. The Chinese carmaker has switched to hybrid and all-electric vehicles and is on track to take Tesla's place as the leading electric carmaker. The first three models for Germany have now been confirmed. At Nordex, sentiment is improving. The share price has jumped, and a large order gives hope. However, wind turbines and batteries cannot be manufactured without raw materials such as tungsten. Now a German research house has taken a closer look at Almonty Industries. The share is on the verge of a revaluation and has a price potential of 100%.

Read

Commented by Juliane Zielonka on November 17th, 2022 | 13:48 CET

BioNxt Solutions, Pfizer, Bayer - Biotech and pharma stocks in focus

  • Biotechnology
  • Investments

Pharma and biotech companies are still booming. However, large corporations like Pfizer and Bayer need help maintaining their market dominance with long-term studies and patent extensions. Pfizer, in particular, experienced the rush of speed in recent years thanks to the emergency approval of the Covid-19 vaccine. In hindsight, however, voices are growing louder about the potential long-term damage of this market cut. Multi-million dollar lawsuits may result. Positioning itself in the mental health niche, whose market size was USD 381.98 billion in 2020, is BioNxt Solutions. Their mission: to tackle depression, anxiety and PTSD with natural substances. A look at the data.

Read

Commented by Stefan Feulner on November 17th, 2022 | 12:10 CET

Rheinmetall, Defense Metals, Nordex - Top opportunities in critical commodities

  • Mining
  • RareEarths
  • Defense

A quick end to the Ukraine conflict is becoming increasingly remote due to recent events. NATO's military buildup is giving the global defense industry a boom that will likely lift company sales to a new level in the coming years. An important building block for implementing weapons systems is the use of rare earth metals. However, China has a monopoly on the critical raw material value chain, a country that is itself in the midst of an escalating conflict with Taiwan.

Read

Commented by André Will-Laudien on November 17th, 2022 | 11:20 CET

The big catch-up - China Big Tech: Alibaba, Deutsche Bank, TUI and Desert Gold turn up the heat!

  • Travel
  • Investments

Investors increasingly look at the big losers in heavily sold markets because the size of the markdowns identifies potential for the future. Often shares fall because of the general market weakness, but sometimes the operating business also weighs heavy. At the end of the year, there is also "tax-loss selling", especially in North America. We look at some stocks that have suffered significant losses but could now take off again.

Read

Commented by Fabian Lorenz on November 17th, 2022 | 10:40 CET

Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?

  • Space
  • Biotechnology

Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.

Read

Commented by Armin Schulz on November 16th, 2022 | 13:30 CET

BioNTech, Meta Materials, and Amazon - Industry leaders belong in the portfolio

  • metamaterials
  • Technology
  • Biotechnology
  • ecommerce

In 2021, the stock market world was still in order - it had been going nowhere but up for years. That was the peak of the stock hype, and many top dogs in their industries were very expensive from a fundamental point of view. That has changed significantly this year. Due to the Ukraine conflict, rising interest rates and ever-higher inflation, many industry leaders had to make significant losses. Even a drop of 50% was not uncommon. Yet the long-term outlook is good. Now that the stock market is slowly regaining momentum, it is worth taking a look at three companies that are leaders in their field.

Read